ClinicaliQ Trial Snapshot
- Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer — Active Not Recruiting • Phase III • Oncology • NCT02516241.
- Durvalumab alone or combined with tremelimumab compared to chemotherapy for advanced bladder cancer.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer Conditions: Urothelial Cancer Interventions: MEDI4736 (Durvalumab), Tremelimumab, Cisplatin, Carboplatin, Gemcitabine Lead Sponsor: AstraZeneca Planned Enrollment: 1126 participants